search
Back to results

Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases

Primary Purpose

Periodontal Diseases

Status
Recruiting
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
DKF-306
Placebo
Sponsored by
Dongkook Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Periodontal Diseases

Eligibility Criteria

19 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 19 years and older
  • Periodontal diseases
  • Having not less than 16 permanent teeth including at least 4 molars (third molars excluded)
  • Having teeth with not less than 2 sites of both probing pocket depth (PPD) ≥ 4 mm and gingival index (GI) ≥ 2 in at least 2 quadrants
  • Agrees not to use over-the-counters (oral, ointment, toothpaste, film, etc.) or quasi-drugs (gargle and mouthwash) to alleviate or treat the symptoms of gingivitis or periodontitis during the study
  • Voluntarily signed the informed consent form
  • Willing to participate in the study

Exclusion Criteria:

  • Hypersensitivity to ingredients of investigational products
  • Hypersensitivity to Azo dyes, acetylsalicylic acid or other prostaglandin synthase inhibitors
  • Following diseases or state in the mouth:

    1. rampant caries or decayed tooth/teeth remained untreated for a long time
    2. multiple restorations which may be related to periodontal inflammation
    3. poor oral hygiene with heavy plaque or calculus deposition
    4. soft or hard tissue tumor
    5. systemic chronic diseases with oral manifestations
    6. fibrotic gingival enlargement
  • Use of orthodontic appliances or removable partial denture(s)
  • Having teeth or state in need of immediate treatment such as periodontal abscess, a tooth indicated for extraction, etc.
  • History of aggressive periodontitis or acute necrotizing ulcerative gingivitis
  • Received dental treatments such as endodontic treatments or periodontal therapy (including both nonsurgical and surgical therapy) within 3 months from randomization
  • Received the following drugs for more than 2 weeks within 3 months from randomization:

    1. systemic/local antibiotics in the mouth or non-steroidal anti-inflammatory drugs
    2. cyclosporine or corticosteroids
    3. phenytoin, calcium antagonists, anticoagulants or antiplatelets
  • Initiated drugs in treatment of chronic diseases within 3 months from randomization
  • Received the same drug with investigational products within 3 months from randomization
  • Medical conditions or diseases affecting the efficacy and safety of investigational products at the investigator's discretion
  • Heavy smoker (20 cigarettes or more a day)
  • Pregnant or breast-feeding
  • Plans to have a child or unwilling to comply with using medically accepted contraception methods during the study
  • Alcohol or drug abuse
  • Other investigational products or procedures within 3 months from screening
  • Not eligible due to other reasons at the investigator's discretion

Sites / Locations

  • YoungsungRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

DKF-306

Placebo

Arm Description

During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.

During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.

Outcomes

Primary Outcome Measures

Change in gingival index from baseline to Week 12

Secondary Outcome Measures

Change in plaque index from baseline to Weeks 4, 8 and 12
Change in probing pocket depth from baseline to Weeks 4, 8 and 12
Change in clinical attachment level from baseline to Weeks 4, 8 and 12
Change in bleeding on probing (%) from baseline to Weeks 4, 8 and 12
Change in gingival index from baseline to Weeks 4 and 8

Full Information

First Posted
December 27, 2021
Last Updated
December 27, 2021
Sponsor
Dongkook Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05188924
Brief Title
Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases
Official Title
A Multi-center, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
May 22, 2020 (Actual)
Primary Completion Date
June 2022 (Anticipated)
Study Completion Date
December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dongkook Pharmaceutical Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a multi-center, randomized, double-blinded, placebo-controlled study to evaluated the efficacy and safety of DKF-306 in patients with periodontal diseases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
158 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DKF-306
Arm Type
Experimental
Arm Description
During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
During Weeks 1 to 4, 2 tablets, t.i.d. During Weeks 5 to 12, 1 tablet, t.i.d.
Intervention Type
Drug
Intervention Name(s)
DKF-306
Intervention Description
Active ingredients
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Change in gingival index from baseline to Week 12
Time Frame
Weeks 0 and 12
Secondary Outcome Measure Information:
Title
Change in plaque index from baseline to Weeks 4, 8 and 12
Time Frame
Weeks 0, 4, 8 and 12
Title
Change in probing pocket depth from baseline to Weeks 4, 8 and 12
Time Frame
Weeks 0, 4, 8 and 12
Title
Change in clinical attachment level from baseline to Weeks 4, 8 and 12
Time Frame
Weeks 0, 4, 8 and 12
Title
Change in bleeding on probing (%) from baseline to Weeks 4, 8 and 12
Time Frame
Weeks 0, 4, 8 and 12
Title
Change in gingival index from baseline to Weeks 4 and 8
Time Frame
Weeks 0, 4 and 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 19 years and older Periodontal diseases Having not less than 16 permanent teeth including at least 4 molars (third molars excluded) Having teeth with not less than 2 sites of both probing pocket depth (PPD) ≥ 4 mm and gingival index (GI) ≥ 2 in at least 2 quadrants Agrees not to use over-the-counters (oral, ointment, toothpaste, film, etc.) or quasi-drugs (gargle and mouthwash) to alleviate or treat the symptoms of gingivitis or periodontitis during the study Voluntarily signed the informed consent form Willing to participate in the study Exclusion Criteria: Hypersensitivity to ingredients of investigational products Hypersensitivity to Azo dyes, acetylsalicylic acid or other prostaglandin synthase inhibitors Following diseases or state in the mouth: rampant caries or decayed tooth/teeth remained untreated for a long time multiple restorations which may be related to periodontal inflammation poor oral hygiene with heavy plaque or calculus deposition soft or hard tissue tumor systemic chronic diseases with oral manifestations fibrotic gingival enlargement Use of orthodontic appliances or removable partial denture(s) Having teeth or state in need of immediate treatment such as periodontal abscess, a tooth indicated for extraction, etc. History of aggressive periodontitis or acute necrotizing ulcerative gingivitis Received dental treatments such as endodontic treatments or periodontal therapy (including both nonsurgical and surgical therapy) within 3 months from randomization Received the following drugs for more than 2 weeks within 3 months from randomization: systemic/local antibiotics in the mouth or non-steroidal anti-inflammatory drugs cyclosporine or corticosteroids phenytoin, calcium antagonists, anticoagulants or antiplatelets Initiated drugs in treatment of chronic diseases within 3 months from randomization Received the same drug with investigational products within 3 months from randomization Medical conditions or diseases affecting the efficacy and safety of investigational products at the investigator's discretion Heavy smoker (20 cigarettes or more a day) Pregnant or breast-feeding Plans to have a child or unwilling to comply with using medically accepted contraception methods during the study Alcohol or drug abuse Other investigational products or procedures within 3 months from screening Not eligible due to other reasons at the investigator's discretion
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Young-Sung Kim
Phone
+82-2-3010-5987
Email
dumber73@mail.ulsan.ac.kr
Facility Information:
Facility Name
Youngsung
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Young-Sung Kim, M.D.
Phone
+82-2-3010-5987
Email
dumber73@mail.ulsan.ac.kr

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of DKF-306 in Patients With Periodontal Diseases

We'll reach out to this number within 24 hrs